Deutsche Bank
CAMP icon

Deutsche Bank’s CAMP4 Therapeutics CAMP Stock Holding History

Deutsche Bank’s Portfolio CAMP Stock Details CAMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$138K Buy
+31,589
New +$136K ﹤0.01% 3402
2025
Q2 		– Sell
-4,643
Closed -$18.6K – 3624
2025
Q1 		$18.6K Buy
+4,643
New +$22.5K ﹤0.01% 3479

Other funds holding CAMP

JT
Jupiter Topco New York $245B AUM
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Deutsche Bank's CAMP Position: Q2 2026 in Review

Deutsche Bank opened a new position in CAMP4 Therapeutics (CAMP) in Q2 2026: 31,589 shares worth $138K. The stake represents ﹤0.01% of the portfolio and ranks #3402 among its holdings. This is a return to the name: Deutsche Bank previously reported a position in CAMP as recently as Q1 2025.

Deutsche Bank first reported a position in CAMP in Q1 2025 and has held it in 2 quarters since. 61 funds tracked by Wall St. Rank hold CAMP as of Q2 2026.

  • Deutsche Bank held 31,589 shares of CAMP4 Therapeutics worth $138K as of Q2 2026.
  • CAMP4 Therapeutics was a new Deutsche Bank position in Q2 2026.
  • CAMP4 Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #3402 holding.
  • Deutsche Bank first reported a position in CAMP4 Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 61 funds tracked by Wall St. Rank held CAMP4 Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.